Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ITT-5 Mechanisms of Spermatogenesis in Man
NCT02147964 · University of Washington · PHASE2 · withdrawn · last registry update 2019-12-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No funding was obtained for this study.” | – | Registry record, University of Washington |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-12-11Results posted on the registry: Clarus Therapeutics, Inc., Testosterone undecanoate (NCT00911586)
- 2020-12-02Results posted on the registry: Clarus Therapeutics, Inc., Oral testosterone undecanoate (containing 300 mg T) (NCT00924612)
- 2020-10-06Phase 3 first posted: Geron Corporation, Imetelstat + Best Available Therapy (BAT) (NCT04576156)
- 2020-09-25Phase 3 first posted: Luye Pharma Group Ltd., LY01005 3.6 mg + ZOLADEX® 3.6 mg (NCT04563936)
- 2020-09-25Results posted on the registry: Peking University People's Hospital, Berberine plus danazol (NCT03909763)
- 2020-09-11Phase 3 first posted: Unita Complessa di Ostetricia e Ginecologia, dutasteride 5 mg/day + Testosterone Undecanoate (NCT04545450)
- 2020-08-21Phase 3 first posted: University of Miami, Testopel 75mg Drug Implant + Testopel 100mg Drug Implant (NCT04523480)
- 2020-08-17Also stopped (withdrawn): European Organisation for Research and Treatment of Cancer - EORTC, Apalutamide + Luteinising Hormone Releasing Hormone analog agonist (LHRHa) (NCT03488810)
- 2020-08-14Phase 3 first posted: NRG Oncology, Apalutamide + Bicalutamide (NCT04513717)
- 2020-08-12Phase 3 first posted: University of Florida, Bicalutamide 150 Mg Oral Tablet + Placebo (NCT04509999)
- 2020-07-13Phase 3 first posted: Marius Pharmaceuticals, SOV2012-F1 (NCT04467697)
- 2020-07-02Phase 3 first posted: The Stone Research Foundation for Sports Medicine and Arthritis, Aveed 750 MG in 3 ML IM Injection (NCT04456530)
- 2020-05-28Also stopped (terminated): NewLink Genetics Corporation, Docetaxel + HyperAcute®-Lung Immunotherapy (NCT01774578)
- 2020-04-28Results posted on the registry: M.D. Anderson Cancer Center, Flutamide + Leuprolide Acetate (NCT00003645)
- 2020-04-28Also stopped (terminated): M.D. Anderson Cancer Center, Flutamide + Leuprolide Acetate (NCT00003645)
- 2020-04-16Also stopped (withdrawn): Universidade Federal do Paraná, Testosterone gel + Placebos (NCT03176537)
- 2020-04-15Results posted on the registry: University of Colorado, Denver, testosterone cypionate 200mg/ml (NCT02408445)
- 2020-04-14Phase 3 first posted: Orthopedic Institute, Sioux Falls, SD, Testosterone cypionate + Placebos (NCT04345666)
- 2020-03-27Phase 3 first posted: Peking Union Medical College Hospital, Danazol + rhTPO (recombinant human thrombopoietin injection) + Danazol + sodium chloride (NCT04324060)
- 2020-01-18Results posted on the registry: University of Maryland, Baltimore, HLXL (NCT00755326)
- 2020-01-02Results posted on the registry: Imperial College Healthcare NHS Trust, Intrinsa Transdermal testosterone patch (NCT01208038)
- 2019-12-16Results posted on the registry: The University of Texas Medical Branch, Galveston, Insulin High Dose + oxandrolone (NCT00673309)
- 2019-12-05Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Bicalutamide (NCT01251861)
- 2019-11-29Also stopped (terminated): The University of Texas Medical Branch, Galveston, Humatrope + Ketoconazole (NCT00675714)
- 2019-11-22Phase 3 first posted: Sierra Oncology LLC - a GSK company, Momelotinib + Placebo to match danazol (NCT04173494)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision